



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

Patrick Dawson BAILEY

Atty. Ref.: 39-326

Serial No. 10/585,864

Group: 1614

Filed: July 11, 2006

Examiner: Unknown

For: DRUG DELIVERY SYSTEM

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 27, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Patrick Dawson BAILEY
Serial No. 10/585,864

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

49-326

10/585,864

APPLICANT

Patrick Dawson BAILEY

FILING DATE

GROUP

July 11, 2006

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,457,180	10/1995	Zacharie et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO 91/01976	02/1991	WIPO				
WO 99/20649	04/1999	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	International Search Report dated June 22, 2006, issued in connection with PCT/GB2005/000151
	Nakamura et al, Tetrahedron Lettes, Vol. 36, No. 28, 1995, pages 5059-5062
	McKeever et al, Tetrahedron Letters 42 (2001) 2573-2577
	Le et al, Canadian Journal of Physiology and Pharmacology, Vol. 75, No. 1, 1997, pages 9-14
	Clausen et al, Journal of The Chemical Society Perkin Transactions I, No. 4, 1984, pages 785-798
	Lehmann et al, Helvetica Chimica Acta 1999 Switzerland, Vol. 82, No. 11, 1999, pages 1899-1915
	Zacharie et al, Journal of Medicinal Chemistry, Vol. 42, No. 11, 1999, pages 2046-2052
	Lajoie et al, Tetrahedron Letters, Vol. 24, No. 36, 1983, pages 3815-3818
	Brown et al, Tetrahedron Letters, Vol. 28, No. 19, 1987, pages 2171-2174
	Zacharie et al, Tetrahedron, Vo. 49, No. 46, 1993, pages 10489-10500
	La Cour, International Journal of Peptide and Protein Research, Vol. 30, No. 4, 1987, pages 564-571
	Elmore et al, Journal of the Chemical Society, Perkin Transactions 1, No. 5, 1988 pages 1051-1055
	Campbell et al, Journal of the American Chemical Society, Vol. 104, No. 19, 1982, pages 5221-5226
	Lehmann et al, Tetrahedron, Vol. 55, No. 17, 1999, pages 5359-5376
	Yao et al, Bioorganic & Medicinal Chemistry Letters, Vol. 8, No. 6, 1998, pages 699-704
	McKeever et al, Tetrahedron, Vol. 59, No. 15, 2003, pages 2713-2727

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)